← Return to What happens after Tymlos?

Discussion

What happens after Tymlos?

Osteoporosis & Bone Health | Last Active: Sep 22 4:42pm | Replies (66)

Comment receiving replies
@awfultruth

Prolia is certainly impressive if you ignore the side effects and the potentially devastating rebound fractures that happen to some. I think Dr. McCormick offers a strategy of
1. a bone building med,
2. short term Prolia (2-4 doses),
3. following the Prolia with Reclast.
All the while following bone markers in order to avoid a sudden increase in bone breakdown if and when you stop the Prolia. And he warns if you go beyond about 3 doses (if my memory is correct) you have more risk of getting the rebound effect.
I'm thinking about this but it sure makes life more complicated and Prolia's rebound effect is just plain scary to me even with the strategy of following Prolia with Reclast.

Here's an interesting paper comparing Prolia to all the bio-phosphonates. It has charts showing the bone density changes year by year for each where the info is available. Prolia keeps increasing density for 8 years in some studies but there is a drop off at some bone sites around 3 years. The bio-phosphonates usually stop improving your bone after 2 years. All this shown in charts. So, Prolia totally wins in the bone gains department. But the paper doesn't do a through job on the negatives.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426099/

Jump to this post


Replies to "Prolia is certainly impressive if you ignore the side effects and the potentially devastating rebound fractures..."

I think we got the same info from interviews with Dr. McCormick on OP meds. With Prolia, to get maximum benefit with minimal risk, he says 4 doses tops, but, in his opinion, it's better to stop at 3 doses. That was my understanding.

Thanks for sharing the link to the study on gains with Prolia, and each of the bisphosphonates. It's a great reference.

Not surprising that the paper is filled with positives about Prolia while neglecting to mention much about the negatives.

Under the "Conflict of Interest Statement" section:
"OT has received fees from Amgen, GSK, Lilly, Nycomed, MEDA and Takeda as lecturer, consultant and/or scientific advisor."

Also, the report is from 2015 when many of the studies on the rebound effect were not out yet